Clinical trial
Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or…
NCT00324415 · AIDS Malignancy Consortium, Other · Completed
Key facts
| NCT number | NCT00324415 |
|---|---|
| Title | Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer |
| Official title | Phase II Trial of Combined Modality Therapy Plus Cetuximab in HIV-Associated Anal Carcinoma |
| Lead sponsor | AIDS Malignancy Consortium, Other |
| Collaborators | National Cancer Institute (NCI) NIH The Emmes Company, LLC Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anal Cancer |
| Intervention type | Biological, Drug, Radiation |
| Interventions | cetuximab, cisplatin, fluorouracil, radiation therapy |
| Enrollment | 45 |
| Start date | Sep 1, 2006 |
| Primary completion | Apr 1, 2014 |
| Completion | May 1, 2016 |
| First posted | May 11, 2006 |
| Last update posted | May 30, 2025 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: